NEW YORK (TheStreet) -- MetLife (MET) shares are down 0.8% to $53.60 in after-hours trading today after U.S. financial regulators declared that the financial health insurance company was "strategically important" to the financial health of the U.S. economy.
MetLife had been fighting the designation by the Financial Stability Oversight Council due to the added scrutiny the company now faces as a result of the ruling.
MetLife has to increase the amount of capital in its reserves to cushion against major potential losses, limit its use of borrowed money and submit to inspections by examiners, according to the Associated Press.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
TheStreet Ratings team rates METLIFE INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate METLIFE INC (MET) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins."
Highlights from the analysis by TheStreet Ratings Team goes as follows: